PT  - JOURNAL ARTICLE
AU  - Undurraga, Eduardo A.
AU  - Chowell, Gerardo
AU  - Mizumoto, Kenji
TI  - Case fatality risk by age from COVID-19 in a high testing setting in Latin America: Chile, March-May, 2020
AID  - 10.1101/2020.05.25.20112904
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.25.20112904
4099  - http://medrxiv.org/content/early/2020/05/26/2020.05.25.20112904.short
4100  - http://medrxiv.org/content/early/2020/05/26/2020.05.25.20112904.full
AB  - Background Early severity estimates of COVID-19 are critically needed to better assess the potential impact of the ongoing pandemic in different socio-demographic groups. Using real-time epidemiological data from Chile, the nation in Latin America with the highest testing rate for COVID-19, we derive delay-adjusted severity estimates by age group as of May 18th, 2020.Methods We employed statistical methods and daily series of age-stratified COVID-19 cases and deaths reported in Chile to estimate the delay-adjusted case fatality rate across six age groups.Results Our most recent estimates of the time-delay adjusted case fatality rate are 0.08% (95% Credible Interval CrI:0.04-0.13%) among persons aged 0-39, 0.61% (95%CrI:0.41-0.87%) for those aged 40-49, 1.06% (95%CrI:0.76-1.40%) for those aged 50-59, 3.79% (95%CrI:3.04-4.66%) for those aged 60-69, 12.22% (95%CrI:10.40-14.38%) for those aged 70-79, and 26.27% (95%CrI:22.95-2980%) for persons aged 80 and over. The overall time-delay adjusted case fatality rate is1.78% (95%CrI: 1.63-1.95%) across all age groups.Conclusions Severity estimates from COVID-19 in Chile indicate a disproportionate impact among seniors, especially among those aged ≥ 70 years. COVID-19 is imposing a high death toll in Latin America. Case fatality rates in Chile suggest the health system is not yet overwhelmed, but the epidemic is expanding fast.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI [grant Number 20H03940]; the Leading Initiative for Excellent Young Researchers from the Ministry of Education, Culture, Sport, Science & Technology of Japan to [KM]; National Science Foundation NSF [grant 1414374] as part of the joint NSF-National Institutes of Health NIH-United States Department of Agriculture USDA Ecology and Evolution of Infectious Diseases program; UK Biotechnology and Biological Sciences Research Council [grant BB/M008894/1] to [GC]; and the Millennium Science Initiative of the Ministry of Economy, Development, and Tourism, Government of Chile, [grant Millennium Initiative for Collaborative Research in Bacterial Resistance].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our research involves only secondary data analysis of publicly available diseases surveillance data (published by the Chilean Ministry of Health in their official webpage). The resulting dataset contains no information that would allow investigators to identify individuals directly or indirectly. As such, our study is exempt from IRB approval under regulations by the Comite Etico Cientifico en Ciencias de la Salud from Pontificia Universidad Catolica de Chile.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study are publicly available in the webpages of the Ministry of Health and the Ministry of Science in Chile. http://www.minciencia.gob.cl/covid19 https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6